Alban E Voppel
Overview
Explore the profile of Alban E Voppel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciampelli S, de Boer J, Voppel A, Corona Hernandez H, Brederoo S, van Dellen E, et al.
Schizophr Bull
. 2023 Mar;
49(Suppl_2):S172-S182.
PMID: 36946532
Background: Language anomalies are a hallmark feature of schizophrenia-spectrum disorders (SSD). Here, we used network analysis to examine possible differences in syntactic relations between patients with SSD and healthy controls....
2.
Corona Hernandez H, Corcoran C, Achim A, de Boer J, Boerma T, Brederoo S, et al.
Schizophr Bull
. 2023 Mar;
49(Suppl_2):S86-S92.
PMID: 36946526
This workshop summary on natural language processing (NLP) markers for psychosis and other psychiatric disorders presents some of the clinical and research issues that NLP markers might address and some...
3.
Voppel A, de Boer J, Brederoo S, Schnack H, Sommer I
Schizophr Bull
. 2022 Oct;
49(Suppl_2):S163-S171.
PMID: 36305054
Background And Hypothesis: Speech is a promising marker to aid diagnosis of schizophrenia-spectrum disorders, as it reflects symptoms like thought disorder and negative symptoms. Previous approaches made use of different...
4.
Oomen P, de Boer J, Brederoo S, Voppel A, Brand B, Wijnen F, et al.
J Psychopathol Clin Sci
. 2022 Mar;
131(2):172-181.
PMID: 35230859
Schizophrenia-spectrum disorders (SSD) are highly heterogeneous in risk factors, symptom characteristics, and disease course outcome. Although speech anomalies have long been recognized as a core symptom of SSD, speech markers...
5.
Koops S, Brederoo S, de Boer J, Nadema F, Voppel A, Sommer I
CNS Neurol Disord Drug Targets
. 2021 Dec;
22(2):152-160.
PMID: 34961469
Background: Depression is a debilitating disorder that at present lacks a reliable biomarker to aid in diagnosis and early detection. Recent advances in computational analytic approaches have opened up new...
6.
Oomen P, Begemann M, Brand B, de Haan L, Veling W, Koops S, et al.
Psychol Med
. 2021 Oct;
53(6):2317-2327.
PMID: 34664546
Background: Cognitive deficits may be characteristic for only a subgroup of first-episode psychosis (FEP) and the link with clinical and functional outcomes is less profound than previously thought. This study...
7.
de Boer J, Brederoo S, Voppel A, Sommer I
Curr Opin Psychiatry
. 2020 Feb;
33(3):212-218.
PMID: 32049766
Purpose Of Review: After more than a century of neuroscience research, reproducible, clinically relevant biomarkers for schizophrenia have not yet been established. This article reviews current advances in evaluating the...
8.
Begemann M, Thompson I, Veling W, Gangadin S, Geraets C, van t Hag E, et al.
Trials
. 2020 Feb;
21(1):147.
PMID: 32033579
Background: Antipsychotic medication is effective for symptomatic treatment in schizophrenia-spectrum disorders. After symptom remission, continuation of antipsychotic treatment is associated with lower relapse rates and lower symptom severity compared to...